Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CStone Pharmaceuticals ( (HK:2616) ) has provided an update.
CStone Pharmaceuticals announced its participation in the European Society for Medical Oncology (ESMO) Congress 2025, where it will present significant clinical advancements from its Pipeline 2.0. The company will debut the first-in-human Phase Ia data for its novel PD-1/VEGF/CTLA-4 trispecific antibody, CS2009, and the Phase Ib study design for its ROR1-targeting antibody-drug conjugate, CS5001. These developments highlight CStone’s commitment to pioneering cancer treatments and enhancing its position in the global oncology market.
More about CStone Pharmaceuticals
CStone Pharmaceuticals, established in 2015 and listed on the Hong Kong Stock Exchange, is an innovation-driven biopharmaceutical company focused on developing anti-cancer therapies. The company is dedicated to addressing unmet medical needs in oncology through research and development.
Average Trading Volume: 14,980,935
Technical Sentiment Signal: Buy
Current Market Cap: HK$10.83B
For a thorough assessment of 2616 stock, go to TipRanks’ Stock Analysis page.